A China-based publicly listed enterprise specialized in blood purification is seeking to collaborate with early stage businesses with advanced technologies that are a strategic fit for its product pipeline. Equity investment size can be flexible but typically ranges from US$0.5-5 million. The firm can also consider collaborative research, licensing, and merger and acquisition. The firm is looking for new opportunities globally with a focus on the US.
The firm is interested in medical devices in the hematology, liver diseases, and cardiovascular diseases fields. The firm prefers post-prototype products with preclinical and clinical validation. Products should have a strategic angle with the firm’s pipeline of products.
The firm is looking for experienced management teams with sector expertise. The firm is interested in distribution rights in China.
If you are interested in more information about this investor and other investors tracked by LSN, please email firstname.lastname@example.org